The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

In this piece, we will look at the stocks Jim Cramer discussed.

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

While the canard that many mergers fail to provide a return to shareholders does not appear to be supported by the data, mergers still occur that appear to be motivated by little more than a CEO& ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a huge consumer ...

On Wall Street, more gains for Nvidia, Amazon and other AI superstars propped up share prices. The S&P 500 rose 0.2% and ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

Palantir Technologies, which came into the day with a stunning 165% gain for the year so far, rose another 3.3%. Traders ...